Selected Publications and Presentations at Conferences

The clinical results of NA-931 and NA-831 have been presented at various international conferences and will be published in medical journals including:


Biomed Industries Presents Global Phase 3 Program of NA-931 as Monotherapy and in Combination With Oral Semaglutide for Obesity at ADA 2026

Click here to view press release
JUNE 10, 2026

Biomed Industries, Inc. Presented Breakthrough Unified Theory Linking Alzheimer’s Disease, Obesity and Cardiovascular Disease at Global Neuroscience Summit 2026

Click here to view press release
MARCH 18, 2026

Biomed Industries Announces Phase 3 Trials of NA-931 Targeting Durable Weight Loss & Lean-Mass Preservation at JPM Week

Click here to view press release
January 19, 2026

Biomed Industries Advances NA-931 Into Two Global Phase 3 Trials Alone and with Semaglutide and Tirzepatide for Obesity

Click here to view press release
January 6, 2026

Results of Phase 2 Clinical Trials of NA-931

Presentation at the 61st Annual Meeting of European Association for the Study of Diabetes (EASD), September 15-19, 2025 in Vienna, AUSTRIA

Phase 2 Clinical Trials Results of NA-931, a Novel Quadruple IGF-1-1, GLP-1, GIP, and Glucagon Receptor Agonist Reduces Body Weight without Muscle Loss

LLOYD L. TRAN et al- Publication is pending

Presentation at Annual Meeting in Endocrinology Society (ENDO 2025), July 12-15, 2025 in San Francsico, California, USA

Phase 2 Clinical Trials Results of NA-931, a Novel Quadruple IGF-1-1, GLP-1, GIP, and Glucagon Receptor Agonist Reduces Body Weight without Muscle Loss

LLOYD L. TRAN et al- Publication is pending

Presentation at American Association of Diabetes, June 20-23, 2025 in Chicago, Illnois USA

NA-931, a Novel Quadruple IGF-1-1, GLP-1, GIP, and Glucagon Receptor Agonist Reduces Body Weight without Muscle Loss

LLOYD L. TRAN; 143-OR: NA-931, a Novel Quadruple IGF-1-1, GLP-1, GIP, and Glucagon Receptor Agonist Reduces Body Weight without Muscle Loss. Diabetes 20 June 2025; 74 (Supplement_1): 143–ORAL PRESENTATION.

https://doi.org/10.2337/db25-143-OR

https://diabetesjournals.org/diabetes/article/74/Supplement_1/143-OR/159475/143-OR-NA-931-a-Novel-Quadruple-IGF-1-1-GLP-1-GIP


Phase 2 Clinical Trials of NA-931 to Study Subjects Who Are Obese with at Least One Weight-Related Comorbid Condition

LLOYD L. TRAN; 2189-LB: Phase 2 Clinical Trials of NA-931 to Study Subjects Who Are Obese with at Least One Weight-Related Comorbid Condition. Diabetes 20 June 2025; 74 (Supplement_1): 2189–LB.

https://doi.org/10.2337/db25-2189-LB

https://diabetesjournals.org/diabetes/article/74/Supplement_1/2189-LB/160162/2189-LB-Phase-2-Clinical-Trials-of-NA-931-to-Study


  • *NA-931: A Novel Quadruple IGF-1, GLP-1, GIP, and Glucagon Receptor Agonist Attenuates Alcohol-Mediated Behavior
    • The 6th World Conference on Addiction Medicine and Psychiatry
    November 25-26, 2024 in Paris, FRANCE

  • * First paper: Neurogenesis Hypothesis- Clinical Trials of NA-831 for Alzheimer’s Disease and NA-901 for Major Depressive Disorder
    • and

  • * Second paper: Combination Therapy Phase 3 Protocol: Placebo-Controlled, Double-Blind, Parallel-Group to Study the Safety and Efficacy of NA-831 in Combination with Lecanemab in Subjects with Early Alzheimer's Disease
    • The 17th annual CTAD conference was held in Madrid, SPAIN
    October 29 – November 1, 2024

  • *NA-931, a Novel Quadruple IGF-1, GLP-1 and GIP Receptor Agonist Reduces Body Weight Without Muscle Loss
    • World Obesity and Weight Management
    October 24-26, 2024 | Baltimore, MD, USA

  • * NA-931, a Novel Quadruple IGF-1, GLP-1 and GIP Receptor Agonist for the treatment of obesity
    • International Conference on Obesity and Weight Management
    October 16-17, 2024 | Las Vegas, NV, USA

  • *A novel quadruple receptor agonist NA-931 reduces obesity and improves mash profile in DIO mice
    *A Phase 2 clinical protocol evaluating efficacy and safety of NA-941 in patients with MASH
    • The 10th Paris MASH International Conference- September 5-6, 2024, in Paris, FRANCE

  • *Neurogenesis Hypothesis and NA-901 for the treatment of Major Depressive Disorder
    • Neurology World Conference, September 4-6, 2024 in San Francisco, California, USA

    List of 5 papers at Alzheimer Association International Conference (AAIC)- July 27-August, 2024 in Philadelphia, PA, USA:

  • *Phase 3 Clinical Protocol: Placebo-Controlled, Double-Blind, Parallel-Group to Study Safety and Efficacy of NA-831 in Combination with Lecanemab in Subjects with Early Alzheimer's Disease

    *Phase 2 Clinical Trials of NA-831 for the Treatment of Alzheimer's Disease and Major Depressive Disorder, support the Neurogenesis Hypothesis

    *Associations Between Alzheimer's Disease and Obesity: Clinical Studies of NA-831 for AD and NA-931 for Obesity

    *Associations Between Alzheimer's Disease and Stroke: Clinical Studies of NA-831 for AD and NA-911 for Stroke

    *Amyloid hypothesis: 20 years of failure in Alzheimer’s research
    • Alzheimer Association International Conference (AAIC)-July 27-August, 2024 in Philadelphia, PA, USA

  • *NA-941, a new metabolite of IGF-1 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
    • The 7th Global MASLD Congress, June 24-25, 2024, London UK

  • * Efficacy and Safety of Semaglutide and Tirzepatide: A Comparative Analysis of Clinical Trials
    • American Diabetes Association-84th Scientific Session- June 21-24, 2024 in Orlando, Florida, USA

  • *A Phase 2 Randomized Placebo-Controlled Clinical Trial to Evaluate the Effect of NA-931 on Weight Loss in Obese Adult Subjects
    • American Diabetes Association-84th Scientific Session- June 21-24, 2024 in Orlando, Florida, USA

  • *A Phase 2 Randomized Placebo-Controlled Clinical Trial to Evaluate the Effect of NA-931 on Weight Loss in Obese Adult Subjects
    • American Association of Clinical Endocrinology, May 9-11, 2024 in New Orleans, Louisiana, USA

  • *Phase 2 clinical trials of NA-931, a new IGF-1/ GLP-1 Agonist for the Treatment of Obesity
    • The 4th International Conference on Diabetes, Endocrinology and Obesity- March 11-12, 2024, Rome, ITALY

  • *Neurogenesis Hypothesis and Clinical Trials of NA-831 for the Treatment of Alzheimer’s Disease and Major Depressive Disorder
    • Clinical Trials on Alzheimer’s Disease (CTAD), October 24-27, 2023 in Boston, MA, USA

  • *A Phase 3 Clinical Trial Protocol to Evaluate the Safety & Efficacy of Combination Therapy of Lecanemab and NA-831
    • Clinical Trials on Alzheimer’s Disease (CTAD), October 24-27, 2023 in Boston, MA, USA

  • *Neurogenesis Hypothesis and Clinical Trials of NA-831 for the Treatment of Alzheimer’s Disease and Major Depressive Disorder
    • Presented at Neurology World Conference- September 15-17, 2023 in Miami, Florida, USA

  • *Amyloid Hypothesis & Neurogenesis Hypothesis: A Case Study Of Phase 2A Clinical Trials Of NA- 831 For The Treatment Of Alzheimer's Disease
    • International Conference on Alzheimer’s Disease and Parkinson’s Disease- March 28-April 1, 2023 Gothenburg, SWEDEN

  • *Amyloid hypothesis: the beginning of the end of a dogma
    • The 6th European Congress on Neurology and Brain Disorders- November 17-18, 2022, Rome, ITALY

  • *Neurogenesis Hypothesis: A case-study – Phase 2A clinical trials of NA-831 for the treatment of Alzheimer’s disease
    • Presented at International Conference on Alzheimer’s disease (AD-PD-2022) – March 15-20, 2022 in Barcelona, SPAIN

  • *A Phase 3 Clinical Trial Protocol to Evaluate the Safety and Efficacy of NA-831 in Patients With Early Alzheimer's Disease
    • Presented at Clinical Trials on Alzheimer’s Disease (CTAD) Conference –November 29-December 2, 2022 in San Francisco, CA, USA

  • *Proposing the Neurogenesis Hypothesis for Alzheimer’s Disease with a case study- Phase 2 Clinical trials of NA-831
    • Alzheimer’s and Dementia, 2022;18(Suppl.10):e061573. https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.061573

  • *A Phase 3 Clinical Trial Protocol to Evaluate the Efficacy and Safety of NA-831 in Subjects with Early Onset of Alzheimer’s Disease
    • Alzheimer’s and Dementia, December 20, 2022 https://doi.org/10.1002/alz.069165

  • *A Randomized Double-Blind Placebo-Controlled Phase 2A Clinical Trial of NA-831 in Patients with MCI and Early Onset of Alzheimer's Disease
    • Alzheimer’s and Dementia, July 1, 2019 https://doi.org/10.1016/j.jalz.2019.08.013

    For further information about our products, please contact us. Contact us